Loading…

Safety of Immunization for Children with Immune Thrombocytopenia

Vaccine hesitancy is a common issue for children with immune thrombocytopenia (ITP) in China. The objective of this paper is to assess the immunization statuses of children with ITP, analyze the possible relationship between immunization and thrombocytopenia, and evaluate the safety of immunization...

Full description

Saved in:
Bibliographic Details
Published in:Vaccines (Basel) 2024-01, Vol.12 (1), p.66
Main Authors: Wang, Xiangshi, Feng, Tianxing, Wang, Chuning, Li, Jingjing, Ge, Yanling, Zhai, Xiaowen, Wang, Hongsheng, Zeng, Mei
Format: Article
Language:English
Subjects:
Citations: Items that this one cites
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by
cites cdi_FETCH-LOGICAL-c511t-c9a6555ed6dc170177a528e71a7c8e06a8ede7135d432ac310e3f15e0893f9e93
container_end_page
container_issue 1
container_start_page 66
container_title Vaccines (Basel)
container_volume 12
creator Wang, Xiangshi
Feng, Tianxing
Wang, Chuning
Li, Jingjing
Ge, Yanling
Zhai, Xiaowen
Wang, Hongsheng
Zeng, Mei
description Vaccine hesitancy is a common issue for children with immune thrombocytopenia (ITP) in China. The objective of this paper is to assess the immunization statuses of children with ITP, analyze the possible relationship between immunization and thrombocytopenia, and evaluate the safety of immunization after ITP remission. We included 186 children with an ITP history and followed up with them for two years after receiving re-immunization recommendations. The participants had an overall age-appropriate vaccine coverage of 57.9%. Vaccine-associated thrombocytopenia occurred in 99 (53.2%, 95% CI = 46.06-60.26) children ranging from 0 to 34 days following immunization, with 14 vaccines involved. One hundred and fifty-four (82.3%, 95% CI = 76.72-87.54) children were advised to restart immunization, whereas 32 (17.2%, 95% CI = 12.46-23.28) were advised to postpone partial or full vaccination. Following the follow-up, 150 (80.6%, 95% CI = 74.37-85.68) children completed the catch-up immunization, whereas 27 (14.5%, 95% CI = 10.17-20.30) partially completed it. Four patients with thrombocytopenia relapsed following the re-immunization. Incomplete catch-up immunization was related to the factors of chronic thrombocytopenia, vaccine-associated thrombocytopenia, and the relapse of ITP following re-immunization. ITP may occur after immunization with vaccines other than measles-containing vaccines. Re-immunization in children with ITP generally does not result in a relapse, regardless of whether the previous thrombocytopenia was vaccine-associated.
doi_str_mv 10.3390/vaccines12010066
format article
fullrecord <record><control><sourceid>gale_doaj_</sourceid><recordid>TN_cdi_doaj_primary_oai_doaj_org_article_e3b4a4eb4679477893e02efbfb9782d9</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><galeid>A780928361</galeid><doaj_id>oai_doaj_org_article_e3b4a4eb4679477893e02efbfb9782d9</doaj_id><sourcerecordid>A780928361</sourcerecordid><originalsourceid>FETCH-LOGICAL-c511t-c9a6555ed6dc170177a528e71a7c8e06a8ede7135d432ac310e3f15e0893f9e93</originalsourceid><addsrcrecordid>eNptkk1vEzEQhlcIRKvSOye0EhcuKWM7_jpBFfERqRIHisTN8nrHiaNdO3h3W4Vfj0NKlVTYB9sz7_tYHk9VvSZwxZiG93fWuRBxIBQIgBDPqnMKUsyYZj-fH-3Pqsth2EAZmjAl5MvqjCnKQUl9Xn38bj2Ouzr5etn3Uwy_7RhSrH3K9WIdujZjrO_DuD6ksb5d59Q3ye3GtMUY7KvqhbfdgJcP60X14_On28XX2c23L8vF9c3McULGmdNWcM6xFa0jEoiUllOFkljpFIKwCttyYrydM2odI4DME46gNPMaNbuolgdum-zGbHPobd6ZZIP5G0h5ZWweg-vQIGvmdo7NXEg9l7IQECj6xjdaKtruWR8OrO3U9Ng6jGO23Qn0NBPD2qzSnSGgKAhCC-HdAyGnXxMOo-nD4LDrbMQ0DYZqIjkXlPMifftEuklTjqVWe1X5BA36SLWy5QUh-lQudnuouZYKNFVMkKK6-o-qzBb74FJEH0r8xAAHg8tpGDL6x0cSMPsuMk-7qFjeHBfn0fCvZ9gfFYTCvQ</addsrcrecordid><sourcetype>Open Website</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2918799095</pqid></control><display><type>article</type><title>Safety of Immunization for Children with Immune Thrombocytopenia</title><source>Publicly Available Content Database</source><source>PubMed Central (PMC)</source><creator>Wang, Xiangshi ; Feng, Tianxing ; Wang, Chuning ; Li, Jingjing ; Ge, Yanling ; Zhai, Xiaowen ; Wang, Hongsheng ; Zeng, Mei</creator><creatorcontrib>Wang, Xiangshi ; Feng, Tianxing ; Wang, Chuning ; Li, Jingjing ; Ge, Yanling ; Zhai, Xiaowen ; Wang, Hongsheng ; Zeng, Mei</creatorcontrib><description>Vaccine hesitancy is a common issue for children with immune thrombocytopenia (ITP) in China. The objective of this paper is to assess the immunization statuses of children with ITP, analyze the possible relationship between immunization and thrombocytopenia, and evaluate the safety of immunization after ITP remission. We included 186 children with an ITP history and followed up with them for two years after receiving re-immunization recommendations. The participants had an overall age-appropriate vaccine coverage of 57.9%. Vaccine-associated thrombocytopenia occurred in 99 (53.2%, 95% CI = 46.06-60.26) children ranging from 0 to 34 days following immunization, with 14 vaccines involved. One hundred and fifty-four (82.3%, 95% CI = 76.72-87.54) children were advised to restart immunization, whereas 32 (17.2%, 95% CI = 12.46-23.28) were advised to postpone partial or full vaccination. Following the follow-up, 150 (80.6%, 95% CI = 74.37-85.68) children completed the catch-up immunization, whereas 27 (14.5%, 95% CI = 10.17-20.30) partially completed it. Four patients with thrombocytopenia relapsed following the re-immunization. Incomplete catch-up immunization was related to the factors of chronic thrombocytopenia, vaccine-associated thrombocytopenia, and the relapse of ITP following re-immunization. ITP may occur after immunization with vaccines other than measles-containing vaccines. Re-immunization in children with ITP generally does not result in a relapse, regardless of whether the previous thrombocytopenia was vaccine-associated.</description><identifier>ISSN: 2076-393X</identifier><identifier>EISSN: 2076-393X</identifier><identifier>DOI: 10.3390/vaccines12010066</identifier><identifier>PMID: 38250879</identifier><language>eng</language><publisher>Switzerland: MDPI AG</publisher><subject>Age ; Antigens ; catch-up immunization ; Chicken pox ; Children ; Diphtheria ; Drug dosages ; Handbooks ; Health aspects ; Hepatitis ; Idiopathic thrombocytopenic purpura ; immune thrombocytopenia ; Immunization ; Management ; Measles ; Mumps ; Parents &amp; parenting ; Pediatrics ; Poliomyelitis ; Prevention ; Remission ; Remission (Medicine) ; Rubella ; Safety ; Steroids ; Surveillance ; Tetanus ; Thrombocytopenia ; vaccine hesitancy ; vaccine-associated thrombocytopenia ; Vaccines ; Whooping cough</subject><ispartof>Vaccines (Basel), 2024-01, Vol.12 (1), p.66</ispartof><rights>COPYRIGHT 2024 MDPI AG</rights><rights>2024 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.</rights><rights>2024 by the authors. 2024</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><cites>FETCH-LOGICAL-c511t-c9a6555ed6dc170177a528e71a7c8e06a8ede7135d432ac310e3f15e0893f9e93</cites><orcidid>0000-0003-1479-6022</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.proquest.com/docview/2918799095/fulltextPDF?pq-origsite=primo$$EPDF$$P50$$Gproquest$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.proquest.com/docview/2918799095?pq-origsite=primo$$EHTML$$P50$$Gproquest$$Hfree_for_read</linktohtml><link.rule.ids>230,314,727,780,784,885,25751,27922,27923,37010,37011,44588,53789,53791,74896</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/38250879$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Wang, Xiangshi</creatorcontrib><creatorcontrib>Feng, Tianxing</creatorcontrib><creatorcontrib>Wang, Chuning</creatorcontrib><creatorcontrib>Li, Jingjing</creatorcontrib><creatorcontrib>Ge, Yanling</creatorcontrib><creatorcontrib>Zhai, Xiaowen</creatorcontrib><creatorcontrib>Wang, Hongsheng</creatorcontrib><creatorcontrib>Zeng, Mei</creatorcontrib><title>Safety of Immunization for Children with Immune Thrombocytopenia</title><title>Vaccines (Basel)</title><addtitle>Vaccines (Basel)</addtitle><description>Vaccine hesitancy is a common issue for children with immune thrombocytopenia (ITP) in China. The objective of this paper is to assess the immunization statuses of children with ITP, analyze the possible relationship between immunization and thrombocytopenia, and evaluate the safety of immunization after ITP remission. We included 186 children with an ITP history and followed up with them for two years after receiving re-immunization recommendations. The participants had an overall age-appropriate vaccine coverage of 57.9%. Vaccine-associated thrombocytopenia occurred in 99 (53.2%, 95% CI = 46.06-60.26) children ranging from 0 to 34 days following immunization, with 14 vaccines involved. One hundred and fifty-four (82.3%, 95% CI = 76.72-87.54) children were advised to restart immunization, whereas 32 (17.2%, 95% CI = 12.46-23.28) were advised to postpone partial or full vaccination. Following the follow-up, 150 (80.6%, 95% CI = 74.37-85.68) children completed the catch-up immunization, whereas 27 (14.5%, 95% CI = 10.17-20.30) partially completed it. Four patients with thrombocytopenia relapsed following the re-immunization. Incomplete catch-up immunization was related to the factors of chronic thrombocytopenia, vaccine-associated thrombocytopenia, and the relapse of ITP following re-immunization. ITP may occur after immunization with vaccines other than measles-containing vaccines. Re-immunization in children with ITP generally does not result in a relapse, regardless of whether the previous thrombocytopenia was vaccine-associated.</description><subject>Age</subject><subject>Antigens</subject><subject>catch-up immunization</subject><subject>Chicken pox</subject><subject>Children</subject><subject>Diphtheria</subject><subject>Drug dosages</subject><subject>Handbooks</subject><subject>Health aspects</subject><subject>Hepatitis</subject><subject>Idiopathic thrombocytopenic purpura</subject><subject>immune thrombocytopenia</subject><subject>Immunization</subject><subject>Management</subject><subject>Measles</subject><subject>Mumps</subject><subject>Parents &amp; parenting</subject><subject>Pediatrics</subject><subject>Poliomyelitis</subject><subject>Prevention</subject><subject>Remission</subject><subject>Remission (Medicine)</subject><subject>Rubella</subject><subject>Safety</subject><subject>Steroids</subject><subject>Surveillance</subject><subject>Tetanus</subject><subject>Thrombocytopenia</subject><subject>vaccine hesitancy</subject><subject>vaccine-associated thrombocytopenia</subject><subject>Vaccines</subject><subject>Whooping cough</subject><issn>2076-393X</issn><issn>2076-393X</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2024</creationdate><recordtype>article</recordtype><sourceid>PIMPY</sourceid><sourceid>DOA</sourceid><recordid>eNptkk1vEzEQhlcIRKvSOye0EhcuKWM7_jpBFfERqRIHisTN8nrHiaNdO3h3W4Vfj0NKlVTYB9sz7_tYHk9VvSZwxZiG93fWuRBxIBQIgBDPqnMKUsyYZj-fH-3Pqsth2EAZmjAl5MvqjCnKQUl9Xn38bj2Ouzr5etn3Uwy_7RhSrH3K9WIdujZjrO_DuD6ksb5d59Q3ye3GtMUY7KvqhbfdgJcP60X14_On28XX2c23L8vF9c3McULGmdNWcM6xFa0jEoiUllOFkljpFIKwCttyYrydM2odI4DME46gNPMaNbuolgdum-zGbHPobd6ZZIP5G0h5ZWweg-vQIGvmdo7NXEg9l7IQECj6xjdaKtruWR8OrO3U9Ng6jGO23Qn0NBPD2qzSnSGgKAhCC-HdAyGnXxMOo-nD4LDrbMQ0DYZqIjkXlPMifftEuklTjqVWe1X5BA36SLWy5QUh-lQudnuouZYKNFVMkKK6-o-qzBb74FJEH0r8xAAHg8tpGDL6x0cSMPsuMk-7qFjeHBfn0fCvZ9gfFYTCvQ</recordid><startdate>20240101</startdate><enddate>20240101</enddate><creator>Wang, Xiangshi</creator><creator>Feng, Tianxing</creator><creator>Wang, Chuning</creator><creator>Li, Jingjing</creator><creator>Ge, Yanling</creator><creator>Zhai, Xiaowen</creator><creator>Wang, Hongsheng</creator><creator>Zeng, Mei</creator><general>MDPI AG</general><general>MDPI</general><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7T7</scope><scope>7XB</scope><scope>8FD</scope><scope>8FE</scope><scope>8FH</scope><scope>8FK</scope><scope>8G5</scope><scope>ABUWG</scope><scope>AEUYN</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BENPR</scope><scope>BHPHI</scope><scope>C1K</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FR3</scope><scope>GNUQQ</scope><scope>GUQSH</scope><scope>HCIFZ</scope><scope>LK8</scope><scope>M2O</scope><scope>M7P</scope><scope>MBDVC</scope><scope>P64</scope><scope>PIMPY</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>Q9U</scope><scope>7X8</scope><scope>5PM</scope><scope>DOA</scope><orcidid>https://orcid.org/0000-0003-1479-6022</orcidid></search><sort><creationdate>20240101</creationdate><title>Safety of Immunization for Children with Immune Thrombocytopenia</title><author>Wang, Xiangshi ; Feng, Tianxing ; Wang, Chuning ; Li, Jingjing ; Ge, Yanling ; Zhai, Xiaowen ; Wang, Hongsheng ; Zeng, Mei</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c511t-c9a6555ed6dc170177a528e71a7c8e06a8ede7135d432ac310e3f15e0893f9e93</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2024</creationdate><topic>Age</topic><topic>Antigens</topic><topic>catch-up immunization</topic><topic>Chicken pox</topic><topic>Children</topic><topic>Diphtheria</topic><topic>Drug dosages</topic><topic>Handbooks</topic><topic>Health aspects</topic><topic>Hepatitis</topic><topic>Idiopathic thrombocytopenic purpura</topic><topic>immune thrombocytopenia</topic><topic>Immunization</topic><topic>Management</topic><topic>Measles</topic><topic>Mumps</topic><topic>Parents &amp; parenting</topic><topic>Pediatrics</topic><topic>Poliomyelitis</topic><topic>Prevention</topic><topic>Remission</topic><topic>Remission (Medicine)</topic><topic>Rubella</topic><topic>Safety</topic><topic>Steroids</topic><topic>Surveillance</topic><topic>Tetanus</topic><topic>Thrombocytopenia</topic><topic>vaccine hesitancy</topic><topic>vaccine-associated thrombocytopenia</topic><topic>Vaccines</topic><topic>Whooping cough</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Wang, Xiangshi</creatorcontrib><creatorcontrib>Feng, Tianxing</creatorcontrib><creatorcontrib>Wang, Chuning</creatorcontrib><creatorcontrib>Li, Jingjing</creatorcontrib><creatorcontrib>Ge, Yanling</creatorcontrib><creatorcontrib>Zhai, Xiaowen</creatorcontrib><creatorcontrib>Wang, Hongsheng</creatorcontrib><creatorcontrib>Zeng, Mei</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Industrial and Applied Microbiology Abstracts (Microbiology A)</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Technology Research Database</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>Research Library (Alumni Edition)</collection><collection>ProQuest Central (Alumni)</collection><collection>ProQuest One Sustainability</collection><collection>ProQuest Central</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>ProQuest Central</collection><collection>ProQuest Natural Science Collection</collection><collection>Environmental Sciences and Pollution Management</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central</collection><collection>Engineering Research Database</collection><collection>ProQuest Central Student</collection><collection>Research Library Prep</collection><collection>SciTech Premium Collection (Proquest) (PQ_SDU_P3)</collection><collection>ProQuest Biological Science Collection</collection><collection>ProQuest_Research Library</collection><collection>Biological Science Database</collection><collection>Research Library (Corporate)</collection><collection>Biotechnology and BioEngineering Abstracts</collection><collection>Publicly Available Content Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central Basic</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><collection>DOAJ Directory of Open Access Journals</collection><jtitle>Vaccines (Basel)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Wang, Xiangshi</au><au>Feng, Tianxing</au><au>Wang, Chuning</au><au>Li, Jingjing</au><au>Ge, Yanling</au><au>Zhai, Xiaowen</au><au>Wang, Hongsheng</au><au>Zeng, Mei</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Safety of Immunization for Children with Immune Thrombocytopenia</atitle><jtitle>Vaccines (Basel)</jtitle><addtitle>Vaccines (Basel)</addtitle><date>2024-01-01</date><risdate>2024</risdate><volume>12</volume><issue>1</issue><spage>66</spage><pages>66-</pages><issn>2076-393X</issn><eissn>2076-393X</eissn><abstract>Vaccine hesitancy is a common issue for children with immune thrombocytopenia (ITP) in China. The objective of this paper is to assess the immunization statuses of children with ITP, analyze the possible relationship between immunization and thrombocytopenia, and evaluate the safety of immunization after ITP remission. We included 186 children with an ITP history and followed up with them for two years after receiving re-immunization recommendations. The participants had an overall age-appropriate vaccine coverage of 57.9%. Vaccine-associated thrombocytopenia occurred in 99 (53.2%, 95% CI = 46.06-60.26) children ranging from 0 to 34 days following immunization, with 14 vaccines involved. One hundred and fifty-four (82.3%, 95% CI = 76.72-87.54) children were advised to restart immunization, whereas 32 (17.2%, 95% CI = 12.46-23.28) were advised to postpone partial or full vaccination. Following the follow-up, 150 (80.6%, 95% CI = 74.37-85.68) children completed the catch-up immunization, whereas 27 (14.5%, 95% CI = 10.17-20.30) partially completed it. Four patients with thrombocytopenia relapsed following the re-immunization. Incomplete catch-up immunization was related to the factors of chronic thrombocytopenia, vaccine-associated thrombocytopenia, and the relapse of ITP following re-immunization. ITP may occur after immunization with vaccines other than measles-containing vaccines. Re-immunization in children with ITP generally does not result in a relapse, regardless of whether the previous thrombocytopenia was vaccine-associated.</abstract><cop>Switzerland</cop><pub>MDPI AG</pub><pmid>38250879</pmid><doi>10.3390/vaccines12010066</doi><orcidid>https://orcid.org/0000-0003-1479-6022</orcidid><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 2076-393X
ispartof Vaccines (Basel), 2024-01, Vol.12 (1), p.66
issn 2076-393X
2076-393X
language eng
recordid cdi_doaj_primary_oai_doaj_org_article_e3b4a4eb4679477893e02efbfb9782d9
source Publicly Available Content Database; PubMed Central (PMC)
subjects Age
Antigens
catch-up immunization
Chicken pox
Children
Diphtheria
Drug dosages
Handbooks
Health aspects
Hepatitis
Idiopathic thrombocytopenic purpura
immune thrombocytopenia
Immunization
Management
Measles
Mumps
Parents & parenting
Pediatrics
Poliomyelitis
Prevention
Remission
Remission (Medicine)
Rubella
Safety
Steroids
Surveillance
Tetanus
Thrombocytopenia
vaccine hesitancy
vaccine-associated thrombocytopenia
Vaccines
Whooping cough
title Safety of Immunization for Children with Immune Thrombocytopenia
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-14T11%3A35%3A29IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-gale_doaj_&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Safety%20of%20Immunization%20for%20Children%20with%20Immune%20Thrombocytopenia&rft.jtitle=Vaccines%20(Basel)&rft.au=Wang,%20Xiangshi&rft.date=2024-01-01&rft.volume=12&rft.issue=1&rft.spage=66&rft.pages=66-&rft.issn=2076-393X&rft.eissn=2076-393X&rft_id=info:doi/10.3390/vaccines12010066&rft_dat=%3Cgale_doaj_%3EA780928361%3C/gale_doaj_%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c511t-c9a6555ed6dc170177a528e71a7c8e06a8ede7135d432ac310e3f15e0893f9e93%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=2918799095&rft_id=info:pmid/38250879&rft_galeid=A780928361&rfr_iscdi=true